

ILLUMINA INC  
Form 8-K  
February 01, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15 (d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of report (Date of earliest event reported): January 28, 2016**

**Illumina, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-35406**  
**(Commission**  
  
**File Number)**

**33-0804655**  
**(I.R.S. Employer**  
  
**Identification No.)**

**5200 Illumina Way, San Diego, California**  
**(Address of principal executive offices)**

**(858) 202-4500**

**92122**  
**(Zip Code)**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**5.02(b)**

On January 28, 2016, Jay T. Flatley, Chief Executive Officer of Illumina, Inc., was elected Chairman of the Board of Directors (the Board) following the resignation of William H. Rastetter, Ph.D. The Board intends to appoint a lead independent director.

Dr. Rastetter stepped off the Board after 17 years of service as a Board member and 11 years as Chairman, in compliance with Illumina governance practices, in order to invest in and serve as an Illumina representative on the board of directors of GRAIL, Inc. GRAIL is Illumina's majority-owned subsidiary formed to enable cancer screening from a simple blood test powered by Illumina sequencing technology.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ILLUMINA, INC.**

Date: February 1, 2016

By: /s/ Charles E. Dadswell  
Charles E. Dadswell  
Senior Vice President, General Counsel and Secretary